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Intermediate DNA methylation is a conserved
signature of genome regulation
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Aleksandar Milosavljevic3, Martin Hirst8,13, Gary D. Stormo1, Ting Wang1 & Joseph F. Costello2
The role of intermediate methylation states in DNA is unclear. Here, to comprehensively
identify regions of intermediate methylation and their quantitative relationship with gene
activity, we apply integrative and comparative epigenomics to 25 human primary cell and
tissue samples. We report 18,452 intermediate methylation regions located near 36% of
genes and enriched at enhancers, exons and DNase I hypersensitivity sites. Intermediate
methylation regions average 57% methylation, are predominantly allele-independent and are
conserved across individuals and between mouse and human, suggesting a conserved
function. These regions have an intermediate level of active chromatin marks and their
associated genes have intermediate transcriptional activity. Exonic intermediate methylation
correlates with exon inclusion at a level between that of fully methylated and unmethylated
exons, highlighting gene context-dependent functions. We conclude that intermediate DNA
methylation is a conserved signature of gene regulation and exon usage.
DOI: 10.1038/ncomms7363 OPEN
1 Department of Genetics, Center for Genome Sciences and Systems Biology, Washington University School of Medicine, St Louis, Missouri 63108, USA.
2 Brain Tumor Research Center, Department of Neurosurgery, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San
Francisco, California 94115, USA. 3 Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas 77030, USA. 4 Institute for
Human Genetics, University of California San Francisco, San Francisco, California 94158, USA. 5Department of Medical Oncology, Center for Molecular
Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA. 6 Department of Pathology, Helen Diller Family Comprehensive
Cancer Center, University of California, San Francisco, San Francisco, California 94115, USA. 7 School of Biological Sciences, University of Essex, Colchester
CO4 3SQ, UK. 8 Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada. 9 Social Genetic &
Developmental Psychiatry Centre, Institute of Psychiatry, King’s College London, London WC2R 2LS, UK. 10 University of Exeter Medical School, Exeter
University, St Luke’s Campus, Exeter EX1 2LU, UK. 11 Department of Pharmacology and the Genome Center, University of California-Davis, Davis, California
95616, USA. 12 The Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA. 13 Centre for High-Throughput Biology and Department of
Microbiology & Immunology, University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z4. Correspondence and requests for materials
should be addressed to T.W. (email: twang@genetics.wustl.edu) or to J.F.C. (email: joseph.costello@ucsf.edu).
NATURE COMMUNICATIONS | 6:6363 | DOI: 10.1038/ncomms7363 | www.nature.com/naturecommunications 1
& 2015 Macmillan Publishers Limited. All rights reserved.
D
NA methylation plays a central role in human develop-
ment and cellular identity1–6. Dynamic CpG methylation
throughout cell differentiation correlates with cell
type-speciﬁc gene regulation and expression levels, with loss of
methylation reﬂecting enhancer or gene activation7–10.
The majority of CpGs in differentiated cells are uniformly
methylated or unmethylated between homologous chromosomes
and within cell populations composed of a single cell type. The
bimodality of DNA methylation implies a binary on–off control
over gene expression, yet a signiﬁcant number of loci throughout
the genome do not ﬁt within this model.
Regions of intermediate methylation (IM) may exhibit allelic
methylation, intercellular variability or clusters of interspersed
methylated and unmethylated CpGs within each cell. A small
number of genes are marked by allele-speciﬁc methylation
(ASM), including imprinting control regions (ICRs), which are
essential for mammalian development11–17. Other IM states,
including non-allelic IM, may also be functional and potentially
dynamically regulated during development7,18,19. The level of
methylation reported in IM regions in prior studies is variable,
but typically much less than the 50% that typiﬁes ICRs7,18,19. The
prevalence of IM states and their function within genetically and
phenotypically homogenous cell populations has been enigmatic.
Here, we use genome-wide DNA methylation proﬁling to
identify and compare IM regions across human tissues and
primary cell types, and among individuals. We deﬁne boundaries
of IM loci by combining two independent and complementary
enrichment-based methods that, respectively, identify methylated
and unmethylated regions of DNA. We then validate and
quantify methylation levels at basepair resolution within IM
regions using whole-genome bisulﬁte sequencing (WGBS) and
methylation array data. We analyse multiple cell types from the
same individual to distinguish cell type epigenetic differences
from genetic effects on the epigenome. We then examine the
relationship between IM states, associated histone marks of gene
regulation, mRNA levels and exon usage from the same samples
used to discover the IM regions. We further use these data, along
with in vivo enhancer assay data and evolutionary conservation,
to discover potential functions of IM states.
Results
IM is closely associated with genes. To identify regions of IM,
we combined two complementary whole-methylome proﬁling
methods: MeDIP-Seq, which targets methylated DNA using an
anti-methylcytosine antibody; and MRE-Seq, which identiﬁes
unmethylated DNA by methylation-sensitive restriction enzyme
digestions. This experimental approach was chosen because
nearly all mapped reads are informative, contrasting to the
inefﬁciency of WGBS in which 70–80% of sequence reads are
uninformative because they lack CpG sites10. Furthermore,
5-methylcytosine and 5-hydroxymethylcytosine are conﬂated in
WGBS, whereas MeDIP/MRE-Seq detect 5-methylcytosine
exclusively. MeDIP/MRE-Seq may also provide greater accuracy
in a minority of loci20. Most importantly, identiﬁcation of IM
with MeDIP/MRE-Seq does not assume a binary state, as IM are
identiﬁed by strong and overlapping signals from each assay. We
applied MeDIP/MRE-Seq8,20–23 to 23 human primary cell and
tissue samples isolated without culturing from three tissue types
and seven donors24, and two biological replicates of the H1
embryonic stem cell line (H1ES)23 (see Methods). The diverse
set of samples we proﬁled allowed controlled comparisons of
different cell types from the same individual, and identical cell
types from different age-matched donors.
A small fraction of CpGs in each sample showed signal
enrichment in both MeDIP-Seq and MRE-Seq, indicating
simultaneous presence of methylated and unmethylated DNA
(Fig. 1a and Supplementary Fig. 1a). We developed a maximum
scoring segment algorithm to deﬁne boundaries of IM regions
representing clusters of neighbouring CpGs with co-occurring
enrichment in MeDIP/MRE-Seq (Methods; Supplementary
Fig. 1b). Altogether, 18,452 unique autosomal IM regions were
detected in one or more samples, containing 2% of the
26.9 million CpGs interrogated. Within IM regions, we estimated
the methylation levels at single CpGs using WGBS from H1ES
cells and Illumina 450K Inﬁnium Methylation Array data from
eight of our samples. WGBS and methylation arrays conﬁrmed
the primarily bimodal genome-wide distribution of fully
methylated and unmethylated CpGs. Individual CpGs within
regions classiﬁed as IM, however, had a mean methylation of 57%
(WGBS) and 58% (arrays; Fig. 1a). In the majority of regions, the
IM state was restricted to one or a subset of tissue or cell types,
although 1,754, or 9%, were present across all tissues studied
(constitutive IM; Fig. 1b–e). Hierarchical clustering based on the
presence or absence of the IM status or based on MeDIP/
MRE-Seq read density at the union set of IM regions strongly
separated cell types isolated from different tissues (Fig. 1c and
Supplementary Fig. 2).
We detected an average of 7,531 autosomal IM regions per
sample, with a mean length of 271 bp. We selected the union of
IM regions across all samples (n¼ 18,452) as a reference set for
further analysis. Over half of IM regions were intragenic or were
within 3 kb of 6,798 autosomal genes (36% of genes; odds
ratio¼ 1.27; P-valueo0.001, w2). IM regions were enriched at
promoters, exons and DNase I hypersensitivity sites (DHSs), and
conﬁrmed 17 of 19 known imprinted loci (Fig. 2a,b and
Supplementary Figs 2a and 3). Thus, IM regions were associated
with a signiﬁcant number of genes and potential regulatory
regions.
Approximately 50% of IM regions overlapped loci identiﬁed as
differentially methylated across cell and tissue types10, consistent
with our observation that IM is often tissue-speciﬁc. However,
most studies comparing methylation between cell types examine
only the binary direction of the methylation change (hypo- or
hypermethylated) rather than the methylation level maintained
within each cell type. Thus, differential methylation as previously
deﬁned does not identify speciﬁc regions as IM. The majority
(69%) of IM regions reported here have not been previously
identiﬁed as having allele-speciﬁc or stable IM states within a
population of cells of a single type7,17,18,25,26 (Supplementary
Fig. 5a,b).
Level of histone modiﬁcation and DHS at IM. To determine
whether IM regions could have regulatory function, we
next performed chromatin immunoprecipitation sequencing
(ChIP-Seq) for selected histone modiﬁcations that demarcate
active regulatory elements, using the same cell samples in which
IM regions were mapped. Within a given sample, we explored
the relationship between DNA methylation level and histone
modiﬁcation levels by comparing histone ChIP-Seq signal at
IM regions to signal at regions that were methylated and
unmethylated in the same sample used for ChIP-Seq, but which
had IM status in other samples. Consistent with prior studies,
the normalized read densities for the active marks of H3K4me1
and H3K4me3 were anti-correlated with DNA methylation.
Interestingly, signal strength for these modiﬁcations at regions
with IM status consistently fell between signals at methylated and
unmethylated sites, providing a novel association of IM with
intermediately active chromatin states (Fig. 2c). Furthermore,
DHS in H1ES cells or in fetal brain had a similar intermediate
state at their IM regions, respectively (Fig. 2d).
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Enhancer regions predicted by chromHMM27 using the cell-
type-matched ChIP-Seq data were more enriched for IM CpGs
than the genomic background of methylated (MeDIP-Seq only)
or unmethylated (MRE-Seq only) CpGs (Supplementary Methods
and Supplementary Fig. 3). We therefore asked if IM regions
coincide with functional regulatory elements deﬁned by in vivo
transgenic reporter assays. Of 70 candidate enhancers deﬁned by
the VISTA project that we also identiﬁed as IM regions, 50 drove
transgene expression in mouse embryos28—a higher validation
rate than VISTA candidates tested from non-IM regions.
Methylation levels of enhancers in the reporter construct are
unknown, however, this result demonstrates that many IM
regions coincide with functional enhancers (Supplementary
Data 1). A small portion of IM regions (9.5%) in fetal brain
also shows increased 5 hmC in fetal brain relative to adult brain29
(Supplementary Fig. 5c).
Level of gene expression and exon inclusion near IM. We
hypothesized that the DNA methylation level in IM regions might
correspond to a difference in the level of transcription of the
associated gene. To examine this relationship, we initially focused
on IM regions occurring within 10 kb of transcription start sites
in breast myoepithelial cells. For comparison, we applied the
same selection criteria to methylated and fully unmethylated
regions in myoepithelial cells that had IM status in other cell
types. Methylated and unmethylated status at these regions
distinguished proximal genes with signiﬁcantly different mean
expression values, following the established inverse correlation
between DNA methylation at enhancers and gene expression.
Remarkably, despite an average DNA methylation level of 63% in
myoepithelial cells based on methylation array, regions with
IM status corresponded to a set of genes with mean expression
distinct from both the methylated and unmethylated sets
(Po0.005, Wilcoxon), suggesting that enhancers with IM are
associated with intermediate levels of gene expression (Fig. 2e).
IM regions were dramatically enriched at coding exons
(Supplementary Methods and Supplementary Fig. 3). Exons
associated with IM were deﬁned as exons with at least one IM
region in the exon or within 1 kb of the exon boundaries. To
investigate the potential function of exonic IM, we calculated
expression of each exon relative to the expression of its gene as a
measure of exon inclusion in the transcript, and compared this
relative expression of IM exons to that of methylated or
unmethylated exon-associated regions. Interestingly, the relation-
ship between methylation and relative exon expression was the
opposite of that observed between expression and methylation at
candidate enhancers. Methylated regions were associated with the
highest exon inclusion, whereas unmethylated regions showed the
lowest exon inclusion, IM states being associated with inter-
mediate inclusion (Po0.001, Wilcoxon; Fig. 2e). These results
were consistent with previous reports using binary classiﬁcation
of DNA methylation states30 and extended the relationship
speciﬁcally to the IM state. Therefore, the level of DNA
methylation could potentially affect either gene expression or
exon inclusion rates in a more quantitative manner than
previously appreciated, although functional assays will be needed.
IM is predominantly allele independent. IM CpGs could reﬂect
ASM or allele-independent methylation (AIM). Interestingly,
most previously identiﬁed ASM has not been connected to
allelic gene expression14,17. To distinguish ASM from AIM,
we identiﬁed heterozygous single-nucleotide polymorphisms
(SNPs) in the autosomal IM regions and determined the allelic
preference of sequencing reads from MeDIP/MRE-Seq, where
ASM segregated heterozygous SNPs between the two assays
(Methods). We identiﬁed a total of 2,072 ASM SNPs (721 unique
across samples) and 5,895 AIM SNPs (3,262 unique; Fig. 3a,b).
We then categorized each IM region as ASM or AIM if it
contained two or more ASM or AIM SNPs (Methods). We
identiﬁed 109 ASM regions and 927 AIM regions (Fig. 3b).
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Figure 1 | IM is predominantly tissue speciﬁc. (a) Top panel, comparison of WGBS methylation levels at CpGs carrying only MRE-seq or MeDIP-seq
reads, and CpGs within IM regions. Bottom panel, comparison of 450k Inﬁnium array methylation levels at CpGs in IM regions and outside of IM
regions (66% of all IM regions overlap one or more methylation array probes). A value of 0 is unmethylated, a value of 1 is fully methylated.
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based on the presence or absence of IM status. Distance metric is Jaccard; clustering method is average. (d) The known imprinted locus in the body
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From these data, we infer that the methylation pattern underlying
a majority of IM regions is allele independent rather than allele
speciﬁc.
ASM should have approximately 50% methylation at indivi-
dual CpGs, whereas IM due to intercellular heterogeneity could
theoretically fall at any IM value. On the methylation arrays,
methylation scores of CpGs within ICRs and our predicted
ASM had a relatively narrow distribution centred near 50%.
Methylation scores at AIM regions peaked near 50% but had a
broader distribution, consistent with the presence of more
intercellular variation at individual CpGs, and potentially across
neighbouring CpGs (Fig. 3c).
We selected 36 high conﬁdence IM regions (based on MeDIP/
MRE-Seq signal strength) for validation by bisulﬁte, PCR, cloning
and sequencing. A total of 35 loci validated as IM (97%),
including 12 of 14 ASM (86%; 2 predicted as ASM were found to
be AIM; Fig. 3a) and 12 of 12 AIM (100%) regions. Interestingly,
the AIM regions exhibited an interspersed mixture of methylated
and unmethylated CpGs on each clone (Supplementary Fig. 6 and
Supplementary Data 2). Thus, the intermediate signals in
H3K4me1, H3K4me3 and DHSs at IM regions cannot be
attributed to fully unmethylated alleles in an ASM conﬁguration.
Potential conﬁgurations include intercellular heterogeneity,
differences in neighbouring nucleosomes and differences between
individual subunits within each nucleosome.
To examine the relationship between ASM and histone
modiﬁcations, we measured allelic preference for histone signals
at ASM loci and compared this to the allelic preference of
MeDIP/MRE-Seq signals at the same locations (Fig. 3d). We
focused on heterozygous SNPs from the two fetal brain samples
with genotype validated by whole-genome sequencing. At loci
classiﬁed as ASM, the active chromatin marks H3K4me3 and
H3K4me1 showed a clear preference for the unmethylated allele,
whereas the repressive mark H3K9me3 had a bias towards the
methylated allele. Interestingly, the repressive mark H3K27me3
preferentially occurred on the unmethylated allele. In contrast,
histone modiﬁcations at AIM and fully unmethylated regions did
not exhibit a strong allelic preference (Supplementary Fig. 4).
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IM state is evolutionarily conserved. As a complementary
comparative epigenomics approach to investigate whether IM
regions may have function, we identiﬁed IM states using MeDIP/
MRE-Seq data from murine embryonic stem (ES) cells and fetal
neurons, taking the union of regions in both cell types as the
reference IM set for mouse. A total of 13,623 IM regions were
detected in the two mouse samples. We then determined how
frequently IM states in the mouse genome were conserved as IM
in human. After mapping mouse IM regions to their syntenic loci
in the human genome, 17.4% directly overlapped human IM
regions, representing a 14-fold enrichment over random expec-
tation (Po0.001, w2), and suggesting signiﬁcant cross-species
conservation of the IM state (Fig. 4a,b). When restricting the
human IM set to only the two human tissues (ES and fetal brain)
that were also proﬁled from mouse, the enrichment increased to
nearly 19-fold, suggesting that tissue speciﬁcity of IM is also
conserved. Averaged phastCons scores over IM regions indicated
DNA sequence conservation that reached its maximum at the
centre of the region, even when coding exons were excluded
(Fig. 4c).
Discussion
We have deﬁned 18,452 discrete regions of the genome that
maintain DNA methylation levels near 50% in one or more cell
types across multiple individuals, and are associated with
intermediately active rather than suppressed gene expression.
Although the precise function of intermediate DNA methylation
states is challenging to prove using current methods, the IM
signature enriches for regions with multiple indicators of
regulatory function, particularly those associated with enhancers.
The intermediate level of active histone modiﬁcation and
chromatin accessibility at IM regions implies these are regulatory
sites distinct from repressive, fully methylated states or
permissive, unmethylated states. Intermediate signals cannot be
explained trivially as cell-type differences within tissues, because
they are equally intermediate in tissue, unsorted peripheral blood
and six highly puriﬁed cell types. The strong association of exonic
IM with an intermediate level of exon inclusion provides
independent validation of the general concept that IM is an
epigenomic signature of context-dependent function. Signiﬁcant
interspecies conservation, and conservation among different
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individuals at IM regions further suggests an important function
and potentially a shared mechanism for their establishment and
maintenance.
Although an individual CpG is either methylated or unmethy-
lated, our results raise the possibility that local clusters of CpGs
provide quantitative instructions for gene regulation or exon
usage that exists stably between fully ‘on’ and ‘off’ states within
single-cell types. Intriguingly, we approximate that 18% or fewer
IM regions are allele-speciﬁcally methylated, whereas the majority
is allele independent, suggesting that the predominant mode of
IM establishment relies on epigenetic heterogeneity at a precise
loci within cell populations. Methods to create and abolish IM
states in a locus-speciﬁc manner will be required to further
examine these possibilities31.
Widespread intercellular and allelic stochasticity of gene
expression has been observed in single-cell mRNA sequencing
data32–34; however, it is not clear why some genes exhibit
stochastic expression while others are uniformly expressed, or if a
biological mechanism might be needed to establish or control
intercellular differences. A quantitative model of epigenetic gene
regulation that includes stable, tissue-speciﬁc intermediate states
may help explain variations in gene activity between cells of the
same type. Although this remains to be proven, it would have
far-reaching implications for the multitude of diseases linked to
disruption of DNA methylation, including the epigenetic
heterogeneity in cancer cells35,36.
Methods
Sample preparation. All assays were performed as part of the repository of
the NIH Roadmap Epigenomics Mapping Centers for the reference Human
Epigenome Atlas37.
Blood. Buffy coats were obtained from the Stanford Blood Center (Palo Alto,
California, USA). Blood was drawn and processed on the same day. Peripheral blood
mononuclear cells (PBMCs) were isolated by Histopaque-1077 (Sigma-Aldrich)
density-gradient centrifugation according to the manufacturer’s protocol. Further
puriﬁcation of memory CD4þ , naive CD4þ and naive CD8þ T lymphocytes was
performed using a RoboSep instrument and the isolation kit for each subpopulation
(EasySep Human Memory CD4þ T Cell Enrichment kit, EasySep Human Naive
CD4þ T Cell Enrichment kit and Custom Human Naive CD8þT Cell Enrichment
kit; STEMCELL Technologies). Total PBMCs were karyotyped (Molecular Diag-
nostic Services) and analysed to determine the percentage of cells in each cell cycle
stage (G0/G1, S and G2/M). PBMC and T-cell subpopulations were stained with
antibodies (anti-CD3 TRI-COLOR (Invitrogen), anti-CD4 PE (BD Biosciences),
anti-CD8 FITC (BD Biosciences), anti-CD4 TRI-COLOR (Invitrogen), anti-
CD45RO PE (Invitrogen), anti-CD45RA FITC (BD Biosciences) and anti-CD8 TRI-
COLOR (Invitrogen)) and analysed by ﬂuorescence-activated cell sorting for purity.
Cells were aliquoted for isolation of either DNA or RNA and were washed in PBS.
Cell pellets for RNA puriﬁcation were resuspended in 1ml of TRIzol reagent
(Invitrogen) and frozen at  80 C. Cell pellets for DNA puriﬁcation were ﬂash
frozen in liquid nitrogen and stored at  80 C. Antibodies used included TRI-
COLOR-conjugated antibody to CD3 (Invitrogen, MHCD0306), Phycoerythrin-
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Figure 4 | The IM state is conserved in syntenic loci in mouse. (a) A novel, tissue-speciﬁc human IM region in an internal exon of DCHS1 shows
conserved IM state at the orthologous exon in mouse. Height for all tracks shows a signal range of 0–50 reads. (b) The pie chart indicates the distance to
the nearest human IM region from each aligned mouse IM region. The bar graph shows the fold-enrichment of overlap between human and mouse IM
regions at the CpG level using the complete set of human IM regions and a set restricted to cell types analogous to those in the mouse IM analysis.
(c) Average phastCons conservation scores over all IM regions and regions that do not overlap coding exons. Scores are based on alignment of 46
vertebrate species.
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conjugated antibody to CD4 (BD Biosciences, 340419), ﬂuorescein isothiocyanate
(FITC)–conjugated antibody to CD8 (BD Biosciences, 561947), TRI-COLOR-con-
jugated antibody to CD4 (Invitrogen, MHCD0406), PE-conjugated antibody to
CD45RO (Invitrogen, MHCD45RO04), FITC–conjugated antibody to CD45RA (BD
Biosciences, MHCD45RA01) and TRI-COLOR-conjugated antibody to CD8 (Invi-
trogen, MHCD0806). All antibodies were used according to the manufacturer’s
instructions.
Breast. Breast tissues were obtained from disease-free premenopausal women
undergoing reduction mammoplasty in accordance with institutional review board
protocol 10-01563 (previously CHR 8759-34462-01). All tissues were obtained as
de-identiﬁed samples and were linked only with a minimal data set (age, ancestry
and, in some cases, parity/gravidity). All study subjects provided written informed
consent. Tissue was dissociated mechanically and enzymatically38. Brieﬂy, tissue
was minced and dissociated in RPMI 1640 with L-glutamine and 25mm HEPES
(Fisher) supplemented with 10% fetal bovine serum (FBS; JR Scientiﬁc),
100Uml 1 penicillin, 100 mgml 1 streptomycin sulfate, 0.25 mgml 1 Fungizone,
50mgml 1 gentamicin sulfate (Lonza), 200Uml 1 collagenase 2 (Worthington)
and 100Uml 1 hyaluronidase (Sigma-Aldrich) at 37 C for 16 h. The cell
suspension was centrifuged at 395 g for 10min, and the pellet was washed with
RPMI 1640 supplemented with 10% FBS. Clusters enriched in epithelial cells
(referred to as organoids) were recovered after serial ﬁltration through 150-mm
nylon mesh (Fisher) and 40-mm nylon mesh (Fisher). The ﬁnal ﬁltrate contained
primarily mammary stromal cells (ﬁbroblasts, immune cells and endothelial cells)
and some single epithelial cells. After centrifugation at 290 g for 5min, the
epithelial organoids and ﬁltrate were frozen for long-term storage. The day of cell
sorting, epithelial organoids were thawed and further digested with 0.5 g l 1
trypsin, 0.5mM EDTA, pH 8.0, and dispase DNase I (STEMCELL Technologies).
Generation of single-cell suspensions was monitored visually. Single-cell
suspensions were ﬁltered through a 40-mm cell strainer (Fisher), spun down and
allowed to regenerate in mammary epithelial cell growth medium (Lonza)
supplemented with 2% FCS for 60–90min at 37 C. This regeneration step enables
quenching of trypsin and re-expression of the cell surface markers before staining,
which was need because their extracellular domains had been cleaved by trypsin.
The single-cell suspension obtained was stained for cell sorting with three
human-speciﬁc primary antibodies, including antibody to CD10 labelled with
PE-Cy5 (BD Biosciences, 555376) to isolate myoepithelial cells, antibody to
CD227/MUC1 labelled with FITC (BD Biosciences, 559774) to isolate luminal
epithelial cells and antibody to CD73 labelled with PE (BD Biosciences, 550257) to
isolate a stem cell-enriched cell population, as well as with biotinylated antibodies
for lineage markers, including antibodies to CD2 (555325), CD3 (555338),
CD16 (555405), CD64 (555526) (all from BD Biosciences), CD31 (Invitrogen,
MHCD3115), CD45 (BioLegend, 304003) and CD140b (BioLegend, 323604) to
speciﬁcally remove haematopoietic (CD16- and CD64-positive), endothelial
(CD31-positive), leukocytic (CD2-, CD3- or CD45-positive) and mesenchymal
(CD140b-positive) lineage cells by negative selection. Sequential incubation with
primary antibodies was performed for 20min at room temperature in PBS with 1%
BSA, and cells were washed in PBS with 1% BSA. Biotinylated primary antibodies
were detected with a secondary antibody to human immunoglobulin labelled with
streptavidin–Paciﬁc Blue conjugate (Invitrogen, S11222). After incubation, cells
were washed once in PBS with 1% BSA, and cell sorting was performed using a
FACSAria II cell sorter (BD Biosciences).
Fetal brain. Post-mortem human fetal neural tissues were obtained from a case of
twin non-syndrome fetuses whose death was attributed to environmental/placental
aetiology. Tissues were obtained with appropriate consent according to the
Partner’s Healthcare/Brigham and Women’s Hospital Institutional Review Board
guidelines (protocol 2010P001144). All samples and tissues were de-identiﬁed and
linked only with a minimal data set (age, sex and brain location). Fetal brain tissue
and fetal neural progenitor cells were derived from manually dissected regions of the
brain (telencephalon), speciﬁcally the neocortex (pallium; GSM669614 and
GSM669615). Tissues were minced and dissociated by mechanical agitation (gentle-
MACS device) during enzymatic treatment with papain according to the manu-
facturer’s protocol (Miltenyi Biotec, Neural Tissue Dissociation kit). Cell suspensions
were then washed twice in Dulbecco’s modiﬁed Eagle medium (DMEM) and plated at
low density in human NeuroCult NS-A medium (STEMCELL Technologies) sup-
plemented with heparin, epidermal growth factor (20 ngml 1) and ﬁbroblast growth
factor (10ngml 1) in ultra-low-attachment cell culture ﬂasks (Corning).
H1 embryonic stem cells. H1 cells were grown in mTeSR1 medium on Matrigel
(BD Biosciences) for ten passages on 10 cm2 plates and harvested at passage 27.
Cells were harvested by scraping before snap freezing for DNA isolation. Cells were
also harvested from passages 30 and 32 and divided for isolation of DNA, RNA and
chromatin23.
Mouse embryonic stem cells and fetal neurons. Mouse embryonic stem cells
(E14) were plated onto gelatin-coated dishes in DMEM (GIBCO), supplemented
with 15% heat-inactivated FBS (GIBCO), 0.055mM mercaptoethanol (GIBCO),
2mM L-glutamine, 0.1mM MEM non-essential amino acid, 5,000Uml 1
penicillin/streptomycin and 1,000Uml 1 of LIF (Millipore ESG1107) in an
incubator set at 37 C and 5% CO2 (MeDIP-Seq: GSM881346; MRE-Seq:
GSM881347). Studies were conducted with the approval of the University of
California San Diego Internal Review Board and Animal Studies Committee.
Cortical neurons from E15 CD-1 mice (Charles River Laboratories) were
processed as described for mouse dorsal root ganglion primary cultures (protocol
number 20140044)39. The animal studies committee at the Washington University
School of Medicine approved the experiments. Gestational day 12.5–13 embryos
were removed and cells were dissected out and dissociated using 0.5ml trypsin/
EDTA (0.05%/0.02%; Tissue Culture Support Center, Washington University,
St Louis, MO, USA) for no longer than 15min at 37 C with two or three times of
gentle shaking by hand. The reaction was stopped by addition of 0.5ml of DMEM/
10% FBS. All subsequent procedures were performed in a laminar ﬂow hood under
sterile condition. Cells were gently triturated by pipetting them up and down with a
sterile P1000 pipetman less than ten times. No cell clumps should be visible after
this trituration. Cell suspensions were centrifuged at 2,000 r.p.m. for 5min at room
temperature. Supernatants were completely removed. Cell pellets were washed
twice with 1ml of DMEM/10% FBS. Cells were resuspended in either DMEM/10%
FBS or growth medium, plated and cultured in neurobasal medium (Invitrogen
#21103-049) with B27 serum-free supplement (Invitrogen #17504-044), glutamine
(5mM) and penicillin/streptomycin. Cells were typically seeded at a density of ‘one
forebrain per 24-well plate’. Neurons were stimulated with KCl (55mM) at 5 days
in vitro for 4 h (ref. 40).
Chromatin immunoprecipitation sequencing. Standard operating procedures for
ChIP-seq library construction are available at http://www.roadmapepigenomics.
org/protocols/type/experimental/. ChIP-seq library construction involves the fol-
lowing protocols in order: (i) cross-linking of frozen cell pellet, (ii) DNA sonication
using Sonic Dismembrator 550 and (iii) SLX-PET protocol for Illumina sample
preparation. Antibodies used in this study were subjected to rigorous quality
assessment to meet Reference Epigenome Mapping Quality Standards (http://
www.roadmapepigenomics.org/protocols) including western blotting of whole-cell
extracts, 384 peptide dot blot (Active Motif MODiﬁed Histone Peptide Array) and
ChIP-seq using control cell pellets (HL60). Antibody vendor, catalogue number
and lot are provided along with ChIP-seq library construction details as part of the
metadata associated with all ChIP-seq data sets and are available through GEO
and the NCBI epigenomics portals (for example, http://www-ncbi-nlm-nih-gov.
beckerproxy.wustl.edu/geo/query/acc.cgi?acc¼ GSM613811). Final library
distributions were calculated using an Agilent Bioanalyzer and quantiﬁed by
ﬂuorometric quantiﬁcation (Qubit, Life Technologies). Libraries were sequenced
using single-end 76 nt sequencing chemistry on an Illumina GAiix or HiSeq2000
following the manufacturer’s protocols (Illumina) as either single or multiplexed
libraries using custom index adapters added during library construction.
Sequencing reads were aligned to NCBI GRCh37-lite reference using Burrows-
Wheeler Alignment tool (BWA) 0.6.2-r126 with default parameters. MethylQA
(an unpublished C programme; available at http://methylqa.sourceforge.net/)
was used to directionally extend aligned reads to the average insert size of DNA
fragments (150 bp) and to generate a bigWig ﬁle for downstream visualization.
Reads with BWA mapping quality scores o 10 were discarded and reads that
aligned to the same genomic coordinate were counted only once.
Methylation-sensitive restriction enzyme-seq. Methylation-sensitive restriction
enzyme (MRE)-seq was performed as in Maunakea et al.22, with modiﬁcations as
detailed below. Five parallel restriction enzyme digestions (HpaII, Bsh1236I,
SsiI(AciI) and Hin6I (Fermentas), and HpyCH4IV (NEB)) were performed, each
using 1 mg of DNA per digest for each of the skin cell type samples. Five units of
enzyme were initially incubated with DNA for 3 h and then an additional ﬁve units
of enzyme was added to the digestion for a total of 6 h of digestion time. DNA was
puriﬁed by phenol/chloroform/isoamyl alcohol extraction, followed by chloroform
extraction using phase lock gels. Digested DNA from the different reactions was
combined and precipitated with one-tenith volume of 3M sodium acetate (pH 5.2)
and 2.5 volumes of ethanol. The puriﬁed DNA was size selected and puriﬁed
(50–300 bp) by gel electrophoresis and Qiagen MinElute extraction. Library
construction was performed as per the Illumina Genomic DNA Sample Prep Kit
protocol with the following modiﬁcations. During the end-repair reaction, T4 DNA
polymerase and T4 PNK were excluded and 1 ml of 1:5 diluted Klenow DNA
polymerase was used. For the adapter ligation reaction, 1 ml of 1:10 diluted PE
adapter oligo mix was used. Ten microlitres from the 30 ml of puriﬁed adapter
ligated DNA was used for the PCR enrichment reaction with PCR PE Primers 1.0
and 2.0. PCR products were size selected and puriﬁed (170–420 bp) by gel
electrophoresis and Qiagen Qiaquick extraction. DNA libraries were checked for
quality by Nanodrop (Thermo Scientiﬁc) and Agilent DNA Bioanalyzer (Agilent).
Reads were aligned to hg19 using the BWA and pre-processed using methylQA
(an unpublished C programme; available at http://methylqa.sourceforge.net/). MRE
reads were normalized to account for differing enzyme efﬁciencies and methylation
values were determined by counting reads with CpGs at fragment ends22. To
enable comparison between MRE-seq data from blood, brain and breast samples
that used three restriction enzymes and skin cell types that used ﬁve restriction
enzymes, skin cell-type MRE reads that resulted from the use of additional
restriction enzymes (Bsh1236I and HpyCH4IV) were removed. Detailed library
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construction protocols for MRE-seq, methylated DNA immunoprecipitation-seq
(MeDIP-seq), ChIP-seq, RNA-seq and miRNA-seq are publicly available at the
NIH Roadmap Epigenomics project website http://www.roadmapepigenomics.org/
protocols/type/experimental/.
Methylated DNA immunoprecipitation-seq. MeDIP-seq was performed as in
Maunakea et al.22 Five micrograms of genomic DNA were sonicated to a fragment
size of B100–400 bp using a Bioruptor sonicator (Diagenode). End-repair,
addition of 30-A bases and PE adapter ligation with 2 mg of sonicated DNA was
performed as per the Illumina Genomic DNA Sample Prep Kit protocol. Adapter-
ligated DNA fragments were size selected to 166–366 bp and puriﬁed by gel
electrophoresis. DNA was heat denatured and then immunoprecipitated with
5-methylcytidine antibody (Eurogentec; 1 mg of antibody per 1 mg of DNA) in
500ml of immunoprecipitation buffer (10 mM sodium phosphate, pH 7.0, 140mM
sodium chloride and 0.05% Triton X-100) overnight at 4 C. Antibody/DNA
complexes were isolated by addition of 1 ml of rabbit anti-mouse IgG secondary
antibody (2.4mgml 1, Jackson Immunoresearch) and 100 ml protein A/G agarose
beads (Pierce Biotechnology) for 2 h at 4 C. Beads were washed six times with
immunoprecipitation buffer and then DNA was eluted in TE buffer with 0.25%
SDS and 0.25mgml 1 of proteinase K for 2 h at 50 C. DNA was then puriﬁed
with the Qiagen Qiaquick kit and eluted in 30 ml EB buffer. Ten microlitres of DNA
were used for a PCR-enrichment reaction with PCR PE Primers 1.0 and 2.0.
PCR products were size selected (220–420 bp) and puriﬁed by gel electrophoresis.
Methylated DNA enrichment was conﬁrmed by PCR on known methylated
(SNRPN and MAGEA1 promoters) and unmethylated (a CpG-less sequence
on chromosome 15 and glyceraldehyde 3-phosphate dehydrogenase promoter)
sequences. DNA libraries were checked for quality by Nanodrop (Thermo
Scientiﬁc) and Agilent DNA Bioanalyzer (Agilent). Reads were aligned to hg19
using BWA and pre-processed using methlyQA.
mRNA-Seq. Standard operating procedures for RNA-Seq library construction are
available at (http://www.roadmapepigenomics.org/protocols/type/experimental/)
or by request. RNA-Seq library construction involves the following SOPs in order:
(i) Puriﬁcation of polyAþ mRNA and mRNA( ) Flow-Through Total RNA
using MultiMACS 96 Separation Unit; (ii) Strand Speciﬁc 96-Well cDNA Synth-
esis; (iii) Strand Speciﬁc 96-well Library Construction for Illumina Sequencing.
Brieﬂy, polyAþ RNA was puriﬁed using the MACS mRNA isolation kit (Miltenyi
Biotec), from 2 to 10 mg of total RNA with a RNA integrity number Z7 (Agilent
Bioanalyzer) as per the manufacturer’s instructions. The process included on-
column DNaseI treatment (Invitrogen). Double-stranded cDNA was synthesized
from the puriﬁed polyAþ RNA using the Superscript II Double-Stranded cDNA
Synthesis kit (Invitrogen) and 200 ng random hexamers (Invitrogen). After ﬁrst
strand synthesis, dNTPs were removed using two volumes of AMPure XP beads
(Beckman Genomics). GeneAmp (Invitrogen) 12.5mM dNTPs blend (2.5mM
dCTP, 2.5mM dGTP, 2.5mM dATP, 5.0mM dUTP) was used in the second strand
synthesis mixture in the presence of 2 mg of ActinomycinD. Double-stranded
cDNA was puriﬁed using two volumes of Ampure XP beads, fragmented using
Covaris E series shearing (20% duty cycle, Intensity 5, 55 s), and used for paired-
end sequencing library preparation (Illumina). Before library ampliﬁcation uridine
digestion was performed at 37 C for 30min following with 10min at 95 C in
Qiagen Elution buffer (10mM Tris-Cl, pH 8.5) with 5U of Uracil-N-Glycosylase
(AmpErase). The resulting single-stranded sequencing library was ampliﬁed by
PCR (10–13 cycles) to add Illumina P5 and P7 sequences for cluster generation.
PCR products were puriﬁed on Qiaquick MinElute columns (Qiagen), and assessed
and quantiﬁed using an Agilent DNA 1000 series II assay and Qubit ﬂuorometer
(Invitrogen), respectively. Libraries were sequenced using paired-end 76 nt
sequencing chemistry on a cBot and Illumina GAiix or HiSeq2000 following the
manufacturer’s protocols (Illumina).
Whole-genome sequencing. Two micrograms of extracted DNA were sheared for
55 s using a Covaris E210 focused ultra-sonicator (Covaris Inc.) at 20% Duty cycle,
5% Intensity and 200 Cycles per burst. The sheared products were separated on an
8% Novex TBE gel (Invitrogen Canada, Inc.) and the 300–500 bp size fraction was
excised and eluted into 300 ml of elution buffer containing 5:1 (vol/vol) LoTe
(3mM Tris-HCl, pH 7.5, 0.2mN EDTA)/7.5M ammonium acetate. The elute was
puriﬁed from the gel slurry by centrifugation through a Spin-X centrifuge tube
ﬁlter (Fisher Scientiﬁc Ltd) and EtOH precipitated. A paired-end library was
constructed from the puriﬁed DNA following Illumina’s protocol (Illumina Inc.).
Brieﬂy, the DNA was subjected to end-repair and phosphorylation by T4 DNA
polymerase, Klenow DNA Polymerase and T4 Polynucleotide Kinase, respectively,
in a single reaction, then 30 A overhangs were generated by Klenow fragment (30 to
50 exo minus). The modiﬁed DNA fragments were ligated to Illumina PE adapters,
and the adapter-ligated products puriﬁed through a QIAquick spin column
(Qiagen Inc.). The ligation products were subjected to six to ten cycles of PCR
ampliﬁcation using Illumina’s PE primer set and Phusion DNA Polymerase
(Thermo Fisher Scientiﬁc Inc.). The ampliﬁed products were separated from non-
ampliﬁable damaged DNA fragments and adapter products on an 8% Novex TBE
gel (Invitrogen Canada, Inc.) and puriﬁed as above. The puriﬁed Illumina library
was assessed using an Agilent DNA 1000 Series II assay (Agilent Technologies
Canada Inc.), quantiﬁed by qPCR according to the KAPA Biosystems Library
Quantiﬁcation Kit protocol (D-Mark Biosciences) and sequenced on Illumina’s
HiSeq2000 machines using paired-end 101 nt chemistry.
Illumina 450K Inﬁnium array. Bisulﬁte conversion was performed on 1 mg of
genomic DNA using the EZ DNA methylation kit (Zymo Research) as per the
manufacturer’s alternative incubation conditions protocol. The bisulﬁte-converted
DNA was ampliﬁed and hybridized to an Inﬁnium HumanMethylation450
beadchip (Illumina) following the Inﬁnium HD methylation assay protocol at the
UCSF Genomics Core facility. Methylation levels (beta values) were determined
using the Methylation Module of the Illumina GenomeStudio software.
Bisulﬁte treatment and library construction for WGBS. One to ﬁve micrograms
of gDNA were sonicated to an approximate size range of 200–400 bp. Size selection
was achieved by PAGE gel and yielded DNA fragments of 200–300 bp. DNA
was quantiﬁed by ﬂuorescent incorporation (Qubit, Invitrogen). The library
preparation included end-repair, an addition with NEBNext DNA library prep
reagent set for Illumina (NEB) or Illumina Sample Prep Kit reagents. Methylated
adaptors were ligated and size selection (325–525 bp) was performed to remove
excess free adaptors. The ligated DNA was quantiﬁed by Qubit, and approximately
100 ng DNA was used for bisulﬁte conversion. Methylated-adaptor ligated to
unmethylated lambda-phage DNA (Promega) was used as an internal control for
assessing the rate of bisulﬁte conversion. The ratio of target library to Lambda was
1,600:1. Bisulﬁte conversion of the methylated adapter-ligated DNA fragments
followed the Formalin-ﬁxed, Parafﬁn-embedded Tissue Samples Protocol from
Qiagen’s Epitect Bisulﬁte Kit. Cleanup of the bisulﬁte-converted DNA was per-
formed, and a second round of conversion was applied. Enrichment of adaptor-
ligated DNA fragments was accomplished by dividing the template into ﬁve ali-
quots followed by eight cycles of PCR with Illumina PE PCR primers. Post PCR
size-selection of the PCR products from the ﬁve reactions was achieved by PAGE
gel. Following 100 bp paired-end sequencing on a HiSeq2000, sequence reads were
aligned and processed through the Bismark pipeline.
Targeted bisulﬁte PCR and sequencing. Further validation of genome-wide data,
particularly sites with apparent intermediate DNA methylation, was performed by
bisulﬁte sequencing. Total genomic DNA underwent bisulﬁte conversion following
established protocol41 with a modiﬁed conversion conditions of: 95 C for 1min,
50 C for 59min for a total of 16 cycles. The regions of interest were ampliﬁed with
bisulﬁte PCR primers and were subsequently cloned using pCR2.1/TOPO
(Invitrogen). Single colony PCR and sequencing (QuintaraBio) provided contigs
that were aligned for analysis.
Genomic features. CpG islands, untranslated regions (UTRs), gene bodies, exons
and introns were RefSeq gene annotations downloaded from the UCSC Genome
Browser (hg19). Promoters were deﬁned as the 3-kb upstream of the transcription
start site (TSS) for all RefSeq genes. Intergenic regions were deﬁned as all regions
outside RefSeq gene bodies and promoters.
IM detection algorithm. We developed a maximum scoring segment algorithm to
identify regions of overlapping MeDIP-Seq and MRE-Seq signals (Supplementary
Fig. 1). For each sample, total MeDIP-Seq read counts were normalized to 50M, and
MRE-Seq read counts were normalized to 35M (ref. 20). Given normalized MeDIP-
Seq and MRE-Seq read densities across all CpGs, the algorithm traces through each
CpG sequentially, comparing read counts from both assays. An arbitrary score
proportional to the read density was increased when the signals overlapped and
decreased when they did not, and an additional penalty proportional to the distance
between CpGs was assigned. When the score returned to zero at some distance
following the initialization of an IM region, the end point of the region was deﬁned
as the position with the highest score following the start site.
The IM detection algorithm and related data sets can be downloaded at http://
epigenome.wustl.edu/Intermediate_Methylation/.
IM data ﬁlters. To limit the false detection of IM, we determined a length and
score threshold by comparing IM calls derived from our data to calls from ran-
domly shufﬂed data. Paired MeDIP-Seq and MRE-Seq read counts were randomly
reassigned to CpGs, maintaining their paired relationship. The length and score
distributions of IM calls from 1,000 random simulations were then compared with
actual distributions, and cutoffs were selected to achieve an estimated false-positive
rate of less than 1%. The minimum score was therefore set to 8.0, and the
minimum length set to 100 bp (length cutoff was applied to the reference IM set).
Reference IM list assembly. The reference list of IM regions is intended as a
summary of the IM landscape across all available samples, and represents the union
of all IM regions that passed the data ﬁlters. IM regions within 100 bp were merged
across all samples. We additionally required each reference list IM region to be
present in at least 2 of the 25 samples analysed to further reduce false positives.
These tasks were performed using applications from the BEDtools suite42.
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The reference set and sample-speciﬁc IM regions can be found at http://
epigenome.wustl.edu/Intermediate_Methylation/.
Hierarchical clustering. To compare methylation at IM regions across all samples,
we clustered samples based on three separate metrics: MeDIP-Seq read counts
(distance metric¼Canberra); MRE-Seq read counts (distance metric¼Canberra)
and binary presence or absence of IM state for each sample (distance metric¼
Jaccard). We performed hierarchical clustering separately for each metric
(clustering method¼ average).
DNase I hypersensitivity. The set of DHSs was previously generated for the
ENCODE database by combining peak calls from 41 different cell lines43.
VISTA enhancer validation. Human and mouse IM regions were intersected with
the complete set of VISTA enhancers. The VISTA Project selects candidate
enhancers based on ChIP-Seq and sequence conservation28. Regions were tested
using in vivo reporter assays within mammalian embryos.
SNP heterozygosity and ASM tests. We analysed only SNPs that fell within
reference IM regions, had a minimum read coverage of nine reads in both MeDIP
and MRE assays (a maximum read cutoff of 100 was also applied to MRE data to
limit inﬂuence of PCR bias), and were previously annotated in the database of
single-nucleotide polymorphisms (dbSNPs)44. We called a SNP heterozygous if
each allele was represented in at least 30% of MeDIP or MRE reads. As whole-
genome sequencing data are available for one of the twin fetal brain samples, we
measured the accuracy of the predicted genotypes for each of the corresponding
twin brain samples. At loci where genotype was known from whole-genome
sequencing, our criteria for predicting heterozygosity from MeDIP/MRE-Seq
achieved a false-positive rate below 3% for each sample.
Of the SNPs categorized as heterozygous, we further classiﬁed them as allele-
speciﬁcally methylated if they met the following criteria: (i) At least 75% of MeDIP-
Seq reads contained the same allele identity at the heterozygous locus, whereas at
least 75% of MRE reads contained a variant allele; (ii) at least one assay (MeDIP-
Seq or MRE-Seq) showed a statistically signiﬁcant skew towards one allele
(Po0.01, Fisher’s exact test).
Heterozygous SNPs qualiﬁed as allele-independent methylation if they met the
following criteria: (i) neither MeDIP-Seq nor MRE-Seq had more than 70% of reads
with the same allele identity at the heterozygous SNP locus; (ii) neither assay showed
a statistically signiﬁcant skew towards an allele (P40.01, Fisher’s exact test).
We classiﬁed an IM region as ASM if it contained two or more ASM SNPs from
any sample and no AIM SNPs. Similarly, we classiﬁed an IM region as AIM if it
contained two or more AIM SNPs and no ASM SNPs. One hundred and thirty-six
regions contained both ASM and AIM SNPs, and were ignored.
Comparing regions with different methylation levels. To compare ChIP-Seq
signal levels between similarly sized and distributed IM, methylated and
unmethylated regions, we examined regions that fell within the boundaries of the
union of all sample IM regions, which are IM in at least one but not necessarily all
samples. In a given sample, a region was deﬁned as unmethylated if it carried four
or more MRE-Seq reads and no MeDIP-Seq reads over at least 75% of CpGs within
the region. Conversely, a region was deﬁned as methylated if it carried four or more
MeDIP-Seq reads and no MRE-Seq reads at 75% of CpGs or greater. These region
deﬁnitions were used for comparison of histone modiﬁcations, DHS levels and
expression of nearby genes.
Histone and DHS signals were measured in 100 bp bins starting from the centre
of each region and extending ±5 kb. Signal level was calculated as reads per
kilobase per millions of reads sequenced (RPKM), and a generalized additive model
was used to approximate the shape of the signal within each group of regions
(methylated, unmethylated and IM) across all bins within a 95% conﬁdence
interval45. CD8 Naı¨ve and PBMC ChIP-Seq were taken from donors that were not
included in the IM analysis (CD8N H3K4me3: GSM613811; CD8N H3K4me1:
GSM613814; PBMC H3K4me3: GSM1127126; PBMC H3K4me1: GSM1127143).
DNase-Seq data were from H1ES and fetal brain donors not included in the IM
analysis (H1ES: GSM878616, fetal brain: GSM878651).
Gene expression and relative exon expression. Methylated, unmethylated and
IM regions were associated with NCBI Reference Sequence (RefSeq) genes if they
fell within 10 kb of the transcription start site of that gene (Total gene-associated
regions: IM¼ 6,776; methylated¼ 3,270; unmethylated¼ 5,605). Gene expression
levels were measured as RPKM for each annotated gene transcript associated with a
region.
Regions were associated with exons if they occurred within 1 kb of the exon (IM
exons¼ 14,336; methylated exons¼ 6,642; unmethylated exons¼ 9,331). Relative
exon expression was measured using the following formula:
Relative Exon Expression ¼ Re Rt ð1Þ
where Re is the RPKM value for a given exon and Rt is the RPKM value for the
transcript containing that exon.
Comparison of human and mouse IM. Mouse coordinates (mm9) were mapped
to orthologous human regions using the UCSC LiftOver tool with minMatch
parameter set to 0.8 (80% sequence identity). Additional data tables can be
downloaded at http://epigenome.wustl.edu/Intermediate_Methylation/.
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